CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY

CW Advisors LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 33.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 334,309 shares of the biopharmaceutical company’s stock after buying an additional 83,835 shares during the quarter. CW Advisors LLC’s holdings in Bristol Myers Squibb were worth $15,475,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. CBIZ Investment Advisory Services LLC grew its position in Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 231 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Bristol Myers Squibb in the 1st quarter valued at about $36,000. REAP Financial Group LLC lifted its position in shares of Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 428 shares in the last quarter. Finally, Flaharty Asset Management LLC purchased a new position in shares of Bristol Myers Squibb in the 1st quarter worth approximately $45,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 5.6%

Shares of NYSE BMY opened at $50.97 on Thursday. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The stock has a market capitalization of $103.76 billion, a PE ratio of 17.22, a P/E/G ratio of 7.52 and a beta of 0.29. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The business’s fifty day moving average price is $45.88 and its 200-day moving average price is $46.71.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.9%. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BMY. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research report on Wednesday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Citigroup lowered their target price on Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating on the stock in a research note on Monday, November 17th. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday. Finally, Scotiabank initiated coverage on shares of Bristol Myers Squibb in a report on Thursday, November 13th. They set a “sector perform” rating and a $45.00 price objective for the company. Four research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $54.58.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.